Serina advances SER-252 Parkinson’s trial to second cohort following safety review
An independent Safety Monitoring Committee recommended advancement to Cohort 2 of the Phase 1b registrational study of SER-252 after a blinded review. Serina Therapeutics claims blinded observations from Cohort 1, which evaluated the lowest single-ascending dose, showed a pharmacokinetic profile con
<p>An independent Safety Monitoring Committee recommended advancement to Cohort 2 of the Phase 1b registrational study of SER-252 after a blinded review. Serina Therapeutics claims blinded observations from Cohort 1, which evaluated the lowest single-ascending dose, showed a pharmacokinetic profile con</p>